News
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Nov 15, 2023
Continuing to Advance Regenerative Therapies for Diabetes and Chronic Lower Back Pain Strong Financial Position with No Long-Term Debt PHOENIX, Nov. 15, 2023 /PRNewswire/ -- Creative Medical...
-
Oct 10, 2023
Company reaches next clinical trial milestone for the intramuscular treatment of Chronic Lower Back Pain with the first novel allogenic cellular therapy in the United States PHOENIX, Oct. 10, 2023...
-
Sep 19, 2023
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy,...
-
Jun 28, 2023
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy,...
-
Jun 12, 2023
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy,...
-
Jun 12, 2023
Continued Advancements in Developing Regenerative Therapeutics While Maintaining Strong Financial Position PHOENIX, June 12, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc....
-
Jun 9, 2023
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy,...
-
May 31, 2023
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy,...
-
May 22, 2023
Advancements May Result in Ability to Treat a Broader Patient Population with Immune Disorders PHOENIX, May 22, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical...
-
May 18, 2023
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy,...
-
Apr 12, 2023
-- One-Year Follow-Up Results Confirm Significant Efficacy and No Serious Adverse Effects in Patients Using CELZ-001 for Treating Type 2 Diabetes -- PHOENIX, April 12, 2023 /PRNewswire/ --...
-
Apr 4, 2023Creative Medical Technology Holdings Announces Filing of 2022 Form 10-K and Provides Business Update
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company" or "We") (NASDAQ: CELZ), a biotechnology company working to revolutionize care through the development of...
-
Mar 23, 2023
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a biotechnology company working to revolutionize care through the development of potentially best-in-class regenerative therapeutics,...
-
Mar 21, 2023
Independent Studies Validate Enhanced Clinical Grade Cell Production for Patient Use in Multiple Indications at a Fraction of Current Industry Cost PHOENIX, March 21, 2023 /PRNewswire/ -- Creative...
-
Feb 8, 2023
Company reaches next clinical trial milestone for treatment of Type 1 Diabetes with the first novel allogenic cellular therapy in the dorsal artery of the pancreas in the United States PHOENIX,...
-
Nov 3, 2022
AlloStem™ represents the first novel allogenic cellular therapy in the dorsal artery of the pancreas in the United States PHOENIX, Nov. 3, 2022 /PRNewswire/ -- Creative Medical Technology...
-
Oct 20, 2022
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, neurology, and orthopedics,...
-
Sep 26, 2022
--Two-Year Follow-Up Results Confirm Significant Efficacy and No Serious Adverse Effects in Patients who Underwent the StemSpine® Procedure for Treating Chronic Lower Back Pain -- PHOENIX, Sept....
-
Jul 28, 2022
Three-Year Follow Up Results Confirm Significant Efficacy and No Serious Adverse Effects in Patients receiving OvaStem® Procedure for Treating Primary Ovarian Insufficiency PHOENIX, July 28, 2022...
-
Jun 15, 2022
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to...
-
Apr 29, 2022
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to...
-
Apr 20, 2022
-- Initial experiments demonstrate expeditious potential for high-volume production of ImmCelz® with consistent potency -- PHOENIX, April 20, 2022 /PRNewswire/ -- Creative Medical Technology...
-
Apr 12, 2022
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to...
-
Mar 31, 2022
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to...
-
Mar 23, 2022
--Two-Year Follow-Up Results Confirm Significant Efficacy and No Serious Adverse Effects in Patients Using StemSpine® Procedure for Treating Chronic Lower Back Pain -- PHOENIX, March 23, 2022...